Meeting
2023 ASCO Genitourinary Cancers Symposium
Adrenocortical carcinoma: Report of data from 66 patients with a rare disease at a cancer center.
Authors
Rafael Haikal dos Santos Abduch
AC Camargo Cancer Center, São Paulo, Brazil
Rafael Haikal dos Santos Abduch , Milena Shizue Tariki , Maria Nirvana Formiga , Stephania Martins Bezerra , Giovana Tardin Torrezan , José Augusto Rinck Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 1)
DOI
10.1200/JCO.2023.41.6_suppl.1
Abstract #
1
Poster Bd #
D9
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Inoperable stage IV colorectal cancer with intact primary tumor in patients receiving palliative chemotherapy: Does the response to chemotherapy correlate between primary and metastatic sites? An Irish cancer center experience.
First Author: Ruba Hamed
Poster
2016 Gastrointestinal Cancers Symposium
Time to first-line chemotherapy and travel distance to the cancer center and their relationship to subsequent-line therapies in stage IV CRC.
First Author: Mahjabeen Fatima Iqbal
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A randomized phase II/III study to evaluate the safety and efficacy of disitamab vedotin (DV) plus toripalimab and chemotherapy/trastuzumab as first-line treatment for HER2-expressed, locally advanced, or metastatic gastric cancer.
First Author: Lin Shen
Poster
2023 ASCO Annual Meeting
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
First Author: Martin Reck